NASDAQ · ALVO
Alvotech
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ALVO: Nov 11, 2026
Alvotech Ordinary Shares is expected to report earnings on 11/11/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.01. The reported EPS for the same quarter last year was $-0.02.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.01 | $0.01 | $-0.02 | 3 |
| Dec 2026 | $0.21 | $0.23 | $0.19 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel · MarketBeat- Zacks · Oct 27, 7:15 AM EDTRepligen (RGEN) Q3 Earnings and Revenues Surpass EstimatesRepligen (RGEN) delivered earnings and revenue surprises of +15.22% and +1.30%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Oct 23, 10:53 AM EDTWeekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win(RTTNews) – Healthcare and biotech news this week centred on regulatory approvals, strategic deals, and pivotal clinical data.
- Zacks · Oct 21, 5:43 AM EDTNew Strong Sell Stocks for October 21stALVO, CSIQ and AESI have been added to the Zacks Rank #5 (Strong Sell) List on October 21, 2026.
- Zacks · Oct 21, 4:39 AM EDTNew Strong Sell Stocks for October 20thALVO, CSIQ and AESI have been added to the Zacks Rank #5 (Strong Sell) List on October 20, 2026.
- RTTNews · Oct 20, 5:09 AM EDTFDA Clears New Manufacturing Process For Alvotech's SIMLANDI Biosimilar; Stock Up(RTTNews) – Alvotech (ALVO) announced that the U.S. FDA has approved a new manufacturing process for SIMLANDI (adalimumab-ryvk), the company's biosimilar version of Humira, allowing production using an upgraded process at its Reykjavik, Iceland facility.
- RTTNews · Oct 14, 6:41 AM EDTAlvotech, Advanz Pharma File First Known Biosimilar Application For Eylea 8mg(RTTNews) – Alvotech (ALVO) and Advanz Pharma have submitted a European regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg (aflibercept), marking what the companies say is the first known regulatory submission worldwide for a biosimilar version of the high-dos
- RTTNews · Oct 9, 1:37 PM EDTWeekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) – This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.
- RTTNews · Oct 7, 11:55 AM EDTAlvotech, LOTTE Biologics Sign Deal For U.S. Biosimilar Manufacturing(RTTNews) – Alvotech (ALVO), a biotechnology company focused on biosimilar medicines, said it has entered into a long-term strategic manufacturing agreement with LOTTE Biologics to increase global supply capacity.
- Fintel · Oct 2, 7:13 PM EDTAlvotech Consensus Price Target Increased by 10.13% to $7.40The average one-year price target for Alvotech (NASDAQGM:ALVO) (DB:Z45) has been revised to $7.40 / share. This is an increase of 10.13% from the prior estimate of $6.71 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not cons
- RTTNews · Aug 31, 8:48 AM EDTAlvotech's AVT80 BLA Accepted For FDA Review As Entyvio Biosimilar(RTTNews) – Alvotech (ALVO), a biotechnology company, on Monday announced the acceptance of its Biologics License Application (BLA) for AVT80 by the U.S. Food and Drug Administration (FDA).
- RTTNews · Aug 21, 12:45 PM EDTAlvotech, Lotus Partner To Commercialize Durvalumab, Emicizumab Biosimilars(RTTNews) – Alvotech (ALVO), a global biotechnology company specializing in biosimilar medicines, announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical covering two proposed biosimilars in the U.S. and selected Asian markets.
- MarketBeat · Aug 20, 10:02 AM EDTAlvotech Q2 Earnings Call HighlightsTeva Pharmaceuticals Stock: Unlock Value in This Generic Drug GemAlvotech (NASDAQ:ALVO) said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed full-year reve
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Alvotech from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.